精密腫瘍学の市場規模、シェア、動向分析レポート：製品タイプ別、がんの種類別、最終用途別、地域別、セグメント予測、2025年～2030年

精密腫瘍学市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の精密腫瘍学（プレシジョン・オンコロジー）市場規模は2030年までに2,019億6,000万米ドルに達し、2025年から2030年までのCAGRは8.05％を記録すると予測されています。

精密腫瘍学は、市場製品が遺伝子の変化を特定するために腫瘍の分子プロファイリングに重点を置く成長分野です。現在、この業界では、患者の95％の奏効率が観察され、質調整生存の延長とともに大きな成功を収めています。市場製品は、病院や診療所における患者ケアの改善や、より良い情報に基づいた意思決定の可能性を提供します。また、世界中でがんの有病率が増加していること、臨床試験研究の数が増加していること、精密腫瘍診断における技術の採用が急速に進んでいることも、市場の需要を押し上げると予想されます。

COVID-19の大流行により、がん患者に対する医療が世界中で拡大し、独自の課題を抱えるようになったため、精密腫瘍学市場は大きな影響を受けました。その上、精密腫瘍学を用いた診断と治療の遅れは、がん患者の診断と治療に大きな影響を与えました。しかし、COVID-19の大流行後、精密腫瘍学はより良い治療結果を提供し、がん患者のQOLを向上させるため、市場は急速な需要を獲得しています。

2022年1月、OncXerna Therapeutics, Inc.とExact Sciences Corp.は、米国でOncXernaのTME Panelラボサービスを患者に導入することで合意したと発表しました。これは革新的な遺伝子発現スコアであり、免疫療法や抗血管新生療法に反応する患者を特定するのに役立ちます。さらに同社は、コンパニオン診断薬として、また既存のプレシジョン・オンコロジー・チームとして、バイオファーマ・パートナーを通じ、臨床医にXerna TME Panelへのアクセスを提供することを確信していると付け加えました。

精密腫瘍学市場レポートハイライト

• 製品タイプ別では、特定の遺伝子変異に合わせた標的治療の開発・承認の増加により、治療薬分野が2024年に71.3%の最大売上シェアで市場をリードしました。
• がんの種類別では、乳がん分野が2024年に41.7％の最大収益シェアで市場をリードしました。
• 最終用途別では、病院・診断分野が2024年に46.8％の最大収益シェアで市場をリードしました。病院・診断分野では、精密腫瘍学製品は、遺伝子の変化を特定するための腫瘍の分子プロファイリングに重点を置いているため、世界的に関心が高まっています。
• 北米の精密腫瘍学市場は、2024年に44.0％の最大収益シェアを占めました。この市場の優位性は、個別化治療アプローチを可能にする高度な診断ツールの利用可能性が高まっていることに起因しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 精密腫瘍学市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場牽引要因分析
  • 市場抑制要因分析
• 精密腫瘍学市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析

第4章 精密腫瘍学市場：製品タイプの推定・動向分析

• 製品タイプ市場シェア、2024年および2030年
• セグメントダッシュボード
• 製品タイプ別世界精密腫瘍学市場展望
• 2018年から2030年までの市場規模と予測および動向分析
  • 診断
  • 治療薬

第5章 精密腫瘍学市場：がんの種類の推定・動向分析

• がんの種類別市場シェア、2024年および2030年
• セグメントダッシュボード
• がんの種類別の世界精密腫瘍学市場の展望
• 2018年から2030年までの市場規模と予測および動向分析
  • 乳がん
  • 大腸がん
  • 子宮頸がん
  • 前立腺がん
  • 肺がん
  • その他

第6章 精密腫瘍学市場：最終用途の推定・動向分析

• 最終用途市場シェア、2024年および2030年
• セグメントダッシュボード
• 最終用途別世界精密腫瘍学市場展望
• 2018年から2030年までの市場規模と予測および動向分析
  • 病院と診断
  • 製薬およびバイオテクノロジー
  • ヘルスケアデータ企業

第7章 精密腫瘍学市場：地域の推定・動向分析

• 地域別市場シェア分析、2024年および2030年
• 地域市場ダッシュボード
• 世界地域市場のスナップショット
• 市場規模と予測動向分析、2018年から2030年：
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • Key company market share analysis, 2024
  • Thermo Fisher Scientific Inc.
  • Invitae Corporation
  • Qiagen NV
  • Illumina, Inc.
  • Laboratory Corporation of America Holding
  • Exact Sciences Corporation
  • Rain Oncology Inc.
  • Strata Oncology Inc.
  • Xilis, Inc.
  • Variantyx, Inc.
  • Bioserve
  • Relay Therapeutics
  • Acrivon Therapeutics

List of Tables

• Table. 1 List of Abbreviation
• Table. 2 North America precision oncology market, by product type, 2018 - 2030 (USD Million)
• Table. 3 North America precision oncology market, by cancer type, 2018 - 2030 (USD Million)
• Table. 4 North America precision oncology market, by end use, 2018 - 2030 (USD Million)
• Table. 5 U.S. precision oncology market, by product type, 2018 - 2030 (USD Million)
• Table. 6 U.S. precision oncology market, by cancer type, 2018 - 2030 (USD Million)
• Table. 7 U.S. precision oncology market, by end use, 2018 - 2030 (USD Million)
• Table. 8 Canada precision oncology market, by product type, 2018 - 2030 (USD Million)
• Table. 9 Canada precision oncology market, by cancer type, 2018 - 2030 (USD Million)
• Table. 10 Canada precision oncology market, by end use, 2018 - 2030 (USD Million)
• Table. 11 Mexico precision oncology market, by product type, 2018 - 2030 (USD Million)
• Table. 12 Mexico precision oncology market, by cancer type, 2018 - 2030 (USD Million)
• Table. 13 Mexico precision oncology market, by end use, 2018 - 2030 (USD Million)
• Table. 14 Europe precision oncology market, by product type, 2018 - 2030 (USD Million)
• Table. 15 Europe precision oncology market, by cancer type, 2018 - 2030 (USD Million)
• Table. 16 Europe precision oncology market, by end use, 2018 - 2030 (USD Million)
• Table. 17 UK precision oncology market, by product type, 2018 - 2030 (USD Million)
• Table. 18 UK precision oncology market, by cancer type, 2018 - 2030 (USD Million)
• Table. 19 UK precision oncology market, by end use, 2018 - 2030 (USD Million)
• Table. 20 Germany precision oncology market, by product type, 2018 - 2030 (USD Million)
• Table. 21 Germany precision oncology market, by cancer type, 2018 - 2030 (USD Million)
• Table. 22 Germany precision oncology market, by end use, 2018 - 2030 (USD Million)
• Table. 23 France precision oncology market, by product type, 2018 - 2030 (USD Million)
• Table. 24 France precision oncology market, by cancer type, 2018 - 2030 (USD Million)
• Table. 25 France precision oncology market, by end use, 2018 - 2030 (USD Million)
• Table. 26 Italy precision oncology market, by product type, 2018 - 2030 (USD Million)
• Table. 27 Italy precision oncology market, by cancer type, 2018 - 2030 (USD Million)
• Table. 28 Italy precision oncology market, by end use, 2018 - 2030 (USD Million)
• Table. 29 Spain precision oncology market, by product type, 2018 - 2030 (USD Million)
• Table. 30 Spain precision oncology market, by cancer type, 2018 - 2030 (USD Million)
• Table. 31 Spain precision oncology market, by end use, 2018 - 2030 (USD Million)
• Table. 32 Denmark precision oncology market, by product type, 2018 - 2030 (USD Million)
• Table. 33 Denmark precision oncology market, by cancer type, 2018 - 2030 (USD Million)
• Table. 34 Denmark precision oncology market, by end use, 2018 - 2030 (USD Million)
• Table. 35 Sweden precision oncology market, by product type, 2018 - 2030 (USD Million)
• Table. 36 Sweden precision oncology market, by cancer type, 2018 - 2030 (USD Million)
• Table. 37 Sweden precision oncology market, by end use, 2018 - 2030 (USD Million)
• Table. 38 Norway precision oncology market, by product type, 2018 - 2030 (USD Million)
• Table. 39 Norway precision oncology market, by cancer type, 2018 - 2030 (USD Million)
• Table. 40 Norway precision oncology market, by end use, 2018 - 2030 (USD Million)
• Table. 41 Asia Pacific precision oncology market, by product type, 2018 - 2030 (USD Million)
• Table. 42 Asia Pacific precision oncology market, by cancer type, 2018 - 2030 (USD Million)
• Table. 43 Asia Pacific precision oncology market, by end use, 2018 - 2030 (USD Million)
• Table. 44 Japan precision oncology market, by product type, 2018 - 2030 (USD Million)
• Table. 45 Japan precision oncology market, by cancer type, 2018 - 2030 (USD Million)
• Table. 46 Japan precision oncology market, by end use, 2018 - 2030 (USD Million)
• Table. 47 China precision oncology market, by product type, 2018 - 2030 (USD Million)
• Table. 48 China precision oncology market, by cancer type, 2018 - 2030 (USD Million)
• Table. 49 China precision oncology market, by end use, 2018 - 2030 (USD Million)
• Table. 50 India precision oncology market, by product type, 2018 - 2030 (USD Million)
• Table. 51 India precision oncology market, by cancer type, 2018 - 2030 (USD Million)
• Table. 52 India precision oncology market, by end use, 2018 - 2030 (USD Million)
• Table. 53 Australia precision oncology market, by product type, 2018 - 2030 (USD Million)
• Table. 54 Australia precision oncology market, by cancer type, 2018 - 2030 (USD Million)
• Table. 55 Australia precision oncology market, by end use, 2018 - 2030 (USD Million)
• Table. 56 Thailand precision oncology market, by product type, 2018 - 2030 (USD Million)
• Table. 57 Thailand precision oncology market, by cancer type, 2018 - 2030 (USD Million)
• Table. 58 Thailand precision oncology market, by end use, 2018 - 2030 (USD Million)
• Table. 59 South Korea precision oncology market, by product type, 2018 - 2030 (USD Million)
• Table. 60 South Korea precision oncology market, by cancer type, 2018 - 2030 (USD Million)
• Table. 61 South Korea precision oncology market, by end use, 2018 - 2030 (USD Million)
• Table. 62 Latin America precision oncology market, by product type, 2018 - 2030 (USD Million)
• Table. 63 Latin America precision oncology market, by cancer type, 2018 - 2030 (USD Million)
• Table. 64 Latin America precision oncology market, by end use, 2018 - 2030 (USD Million)
• Table. 65 Brazil precision oncology market, by product type, 2018 - 2030 (USD Million)
• Table. 66 Brazil precision oncology market, by cancer type, 2018 - 2030 (USD Million)
• Table. 67 Brazil precision oncology market, by end use, 2018 - 2030 (USD Million)
• Table. 68 Argentina precision oncology market, by product type, 2018 - 2030 (USD Million)
• Table. 69 Argentina precision oncology market, by cancer type, 2018 - 2030 (USD Million)
• Table. 70 Argentina precision oncology market, by end use, 2018 - 2030 (USD Million)
• Table. 71 Middle East & Africa precision oncology market, by product type, 2018 - 2030 (USD Million)
• Table. 72 Middle East & Africa precision oncology market, by cancer type, 2018 - 2030 (USD Million)
• Table. 73 Middle East & Africa precision oncology market, by end use, 2018 - 2030 (USD Million)
• Table. 74 South Africa precision oncology market, by product type, 2018 - 2030 (USD Million)
• Table. 75 South Africa precision oncology market, by cancer type, 2018 - 2030 (USD Million)
• Table. 76 South Africa precision oncology market, by end use, 2018 - 2030 (USD Million)
• Table. 77 Saudi Arabia precision oncology market, by product type, 2018 - 2030 (USD Million)
• Table. 78 Saudi Arabia precision oncology market, by cancer type, 2018 - 2030 (USD Million)
• Table. 79 Saudi Arabia precision oncology market, by end use, 2018 - 2030 (USD Million)
• Table. 80 UAE precision oncology market, by product type, 2018 - 2030 (USD Million)
• Table. 81 UAE precision oncology market, by cancer type, 2018 - 2030 (USD Million)
• Table. 82 UAE precision oncology market, by end use, 2018 - 2030 (USD Million)
• Table. 83 Kuwait precision oncology market, by product type, 2018 - 2030 (USD Million)
• Table. 84 Kuwait precision oncology market, by cancer type, 2018 - 2030 (USD Million)
• Table. 85 Kuwait precision oncology market, by end use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value-chain-based sizing & forecasting
• Fig. 6 QFD modeling for market share assessment
• Fig. 7 Market formulation & validation
• Fig. 8 Precision Oncology: Market outlook
• Fig. 9 Precision Oncology: Competitive Insights
• Fig. 10 Parent market outlook
• Fig. 11 Related/ancillary market outlook
• Fig. 12 Penetration and growth prospect mapping
• Fig. 13 Industry value chain analysis
• Fig. 14 Precision Oncology Market driver impact
• Fig. 15 Precision Oncology Market Restraint Impact
• Fig. 16 Precision Oncology Market Strategic Initiatives Analysis
• Fig. 17 Precision Oncology market: Product type movement analysis
• Fig. 18 Precision Oncology market: Product type outlook and key takeaways
• Fig. 19 Diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 20 Therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 21 Precision Oncology market: Cancer type movement analysis
• Fig. 22 Precision Oncology market: Cancer type outlook and key takeaways
• Fig. 23 Breast Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 24 Colorectal Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 25 Cervical Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 26 Prostate Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 27 Lung Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 28 Others market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 29 Precision Oncology market: End Use movement analysis
• Fig. 30 Precision Oncology market: End Use outlook and key takeaways
• Fig. 31 Hospitals & Diagnostic Laboratories market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 32 Pharmaceutical & Biotechnology Companies market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 33 Healthcare Data Companies market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 34 North America precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 35 U.S. precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 36 Canada precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 37 Mexico precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 38 Europe precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 39 U.K. precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 40 Germany precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 41 France precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 42 Italy precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 43 Spain precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 44 Sweden precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 45 Norway precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 46 Denmark precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 47 Asia Pacific precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 48 Japan precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 49 China precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 50 India precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 51 Australia precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 52 Thailand precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 53 South Korea precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 54 Latin America precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 55 Brazil precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 56 Argentina precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 57 Middle East and Africa. precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 58 Saudi Arabia precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 59 South Africa precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 60 UAE precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 61 Kuwait precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)

Precision Oncology Market Growth & Trends:

The global precision oncology market size is expected to reach USD 201.96 billion by 2030, registering a CAGR of 8.05% from 2025 to 2030, according to a new report by Grand View Research, Inc. Precision oncology is a growing field where the market products emphasize on molecular profiling of tumors to identify alterations in the gene. Currently, the industry has witnessed major success with a 95% response rate being observed in patients along with extended quality-adjusted life. The market products offer the potential for improved patient care and a better-informed decision-making experience in hospitals and clinics. Alternatively, the increasing prevalence of cancer across the globe, the rising number of clinical trial studies, and the rapid adoption of technology in precision oncology diagnostic is anticipated to boost the market demand.

Due to the COVID-19 pandemic, the precision oncology market had a huge impact as the pandemic exaggerated healthcare across the globe for people living with cancer, possessing a unique set of challenges. Besides, delayed diagnosis and therapeutics using precision oncology have affected cancer patient diagnosis and treatment to a major extent. However, post-COVID-19 pandemic, the market has gained rapid demand as precision oncology offers better therapeutic outcomes and improves the quality of patient life for cancer patients.

In January 2022, OncXerna Therapeutics, Inc. and Exact Sciences Corp. mentioned the agreement to introduce OncXerna's TME Panel lab services for patients in the U.S. It is an innovative gene expression score, which helps identify patients to respond to immunotherapies and anti-angiogenic. Further, the company added that it believes to provide clinician access to the Xerna TME Panel through biopharma partners as a companion diagnostic and existing precision oncology team.

Precision Oncology Market Report Highlights:

• Based on product type, the therapeutics segment led the market with the largest revenue share of 71.3% in 2024, due to the increasing development and approval of targeted treatments tailored to specific genetic mutations.
• Based on cancer type, the breast cancer segment led the market with the largest revenue share of 41.7% in 2024, attributed to increasing awareness for breast cancer screening, diagnosis, and surgical and radiation techniques.
• Based on end-use, the hospitals and diagnostic segment led the market with the largest revenue share of 46.8% in 2024. In hospital and diagnostic, precision oncology products are garnering an increasing amount of interest worldwide as it emphases molecular profiling of tumors to identify alterations in the gene.
• North America precision oncology market dominated with the largest revenue share of 44.0% in 2024. The market dominance can be attributed to the increasing availability of advanced diagnostic tools that enable personalized treatment approaches.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product Type
  • 1.2.2. Cancer Type
  • 1.2.3. End Use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product type outlook
  • 2.2.2. Cancer type outlook
  • 2.2.3. End Use outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Precision Oncology Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising Prevalence of Cancer
    • 3.2.1.2. Advancements in Genomics and Molecular Diagnostics:
    • 3.2.1.3. Supportive Government and Private Sector Initiatives
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High Costs of Precision Oncology Therapies
    • 3.2.2.2. Limited Access to Advanced Diagnostic Technologies:
• 3.3. Precision Oncology Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Precision Oncology Market: Product Type Estimates & Trend Analysis

• 4.1. Product Type Market Share, 2024 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Precision Oncology Market by Product Type Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Diagnostics
    • 4.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.2. Therapeutics
    • 4.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Precision Oncology Market: Cancer Type Estimates & Trend Analysis

• 5.1. Cancer Type Market Share, 2024 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Precision Oncology Market by Cancer Type Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Breast Cancer
    • 5.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.2. Colorectal Cancer
    • 5.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.3. Cervical Cancer
    • 5.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.4. Prostate Cancer
    • 5.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.5. Lung Cancer
    • 5.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.6. Others
    • 5.4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Precision Oncology Market: End Use Estimates & Trend Analysis

• 6.1. End Use Market Share, 2024 & 2030
• 6.2. Segment Dashboard
• 6.3. Global Precision Oncology Market by End Use Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.4.1. Hospitals and Diagnostic
    • 6.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.4.2. Pharmaceutical and Biotechnology
    • 6.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.4.3. Healthcare Data Companies
    • 6.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Precision Oncology Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 7.5. North America
  • 7.5.1. U.S.
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Target disease prevalence
    • 7.5.1.5. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.2. Canada
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. Target disease prevalence
    • 7.5.2.5. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.3. Mexico
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. Target disease prevalence
    • 7.5.3.5. Mexico market estimates and forecasts, 2018 to 2030, (USD Million
• 7.6. Europe
  • 7.6.1. UK
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Target disease prevalence
    • 7.6.1.5. UK market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.2. Germany
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Target disease prevalence
    • 7.6.2.5. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.3. France
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/ reimbursement structure
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. Target disease prevalence
    • 7.6.3.5. France market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.4. Italy
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework/ reimbursement structure
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. Target disease prevalence
    • 7.6.4.5. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.5. Spain
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework/ reimbursement structure
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. Target disease prevalence
    • 7.6.5.5. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.6. Norway
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework/ reimbursement structure
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. Target disease prevalence
    • 7.6.6.5. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.7. Sweden
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Regulatory framework/ reimbursement structure
    • 7.6.7.3. Competitive scenario
    • 7.6.7.4. Target disease prevalence
    • 7.6.7.5. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.8. Denmark
    • 7.6.8.1. Key country dynamics
    • 7.6.8.2. Regulatory framework/ reimbursement structure
    • 7.6.8.3. Competitive scenario
    • 7.6.8.4. Target disease prevalence
    • 7.6.8.5. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Japan
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. Target disease prevalence
    • 7.7.1.5. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.2. China
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Target disease prevalence
    • 7.7.2.5. China market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.3. India
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. Target disease prevalence
    • 7.7.3.5. India market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.4. Australia
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Target disease prevalence
    • 7.7.4.5. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.5. South Korea
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Regulatory framework/ reimbursement structure
    • 7.7.5.3. Competitive scenario
    • 7.7.5.4. Target disease prevalence
    • 7.7.5.5. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.6. Thailand
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Regulatory framework/ reimbursement structure
    • 7.7.6.3. Competitive scenario
    • 7.7.6.4. Target disease prevalence
    • 7.7.6.5. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.8. Latin America
  • 7.8.1. Brazil
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Regulatory framework/ reimbursement structure
    • 7.8.1.3. Competitive scenario
    • 7.8.1.4. Target disease prevalence
    • 7.8.1.5. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.8.2. Argentina
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework/ reimbursement structure
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Target disease prevalence
    • 7.8.2.5. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.9. MEA
  • 7.9.1. South Africa
    • 7.9.1.1. Key country dynamics
    • 7.9.1.2. Regulatory framework/ reimbursement structure
    • 7.9.1.3. Competitive scenario
    • 7.9.1.4. Target disease prevalence
    • 7.9.1.5. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.9.2. Saudi Arabia
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Regulatory framework/ reimbursement structure
    • 7.9.2.3. Competitive scenario
    • 7.9.2.4. Target disease prevalence
    • 7.9.2.5. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.9.3. UAE
    • 7.9.3.1. Key country dynamics
    • 7.9.3.2. Regulatory framework/ reimbursement structure
    • 7.9.3.3. Competitive scenario
    • 7.9.3.4. Target disease prevalence
    • 7.9.3.5. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.9.4. Kuwait
    • 7.9.4.1. Key country dynamics
    • 7.9.4.2. Regulatory framework/ reimbursement structure
    • 7.9.4.3. Competitive scenario
    • 7.9.4.4. Target disease prevalence
    • 7.9.4.5. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. Key company market share analysis, 2024
  • 8.3.2. Thermo Fisher Scientific Inc.
    • 8.3.2.1. Company overview
    • 8.3.2.2. Financial performance
    • 8.3.2.3. Product benchmarking
    • 8.3.2.4. Strategic initiatives
  • 8.3.3. Invitae Corporation
    • 8.3.3.1. Company overview
    • 8.3.3.2. Financial performance
    • 8.3.3.3. Product benchmarking
    • 8.3.3.4. Strategic initiatives
  • 8.3.4. Qiagen N.V.
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Illumina, Inc.
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Laboratory Corporation of America Holding
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Exact Sciences Corporation
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Rain Oncology Inc.
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Strata Oncology Inc.
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Xilis, Inc.
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Variantyx, Inc.
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Bioserve
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Relay Therapeutics
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives
  • 8.3.14. Acrivon Therapeutics
    • 8.3.14.1. Company overview
    • 8.3.14.2. Financial performance
    • 8.3.14.3. Product benchmarking
    • 8.3.14.4. Strategic initiatives